Lupus ABC spearheading a new era of collaboration to advance lupus drug development

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2025-04-01 DOI:10.1038/s41584-025-01247-4

Hoang Nguyen, Teodora P. Staeva

引用次数: 0

Abstract

Despite having a robust drug development pipeline, lupus remains far behind other rheumatic and autoimmune conditions for which dozens of targeted therapies have been developed. Addressing the pervasive, long-standing challenges impeding the field requires a paradigm shift and a patient-powered, community-wide approach, exemplified by the Lupus Accelerating Breakthroughs Consortium (Lupus ABC).

Abstract Image

查看原文本刊更多论文

狼疮ABC率先合作推进狼疮药物开发的新时代

尽管有一个强大的药物开发管道，狼疮仍然远远落后于其他风湿病和自身免疫性疾病，许多靶向治疗已经开发出来。解决普遍存在的、长期阻碍该领域的挑战需要范式转变和以患者为动力的、社区范围的方法，狼疮加速突破联盟（狼疮ABC）就是一个例子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.